Abbott Laboratories (NYSE:ABT) is one of the 12 Set-It-and-Forget-It Stocks to Buy Now. Amid a positive second quarter and a top executive sale, the company gains an expansion opportunity from Medtronic. Abbott Gains Diabetes Tech Expansion Opportunity Following Earnings Beat and Insider Sale Abbott Laboratories (NYSE:ABT) reported a 6.9% increase in sales for the second quarter of 2025. The earnings report, announced on July 17, 2025, also highlighted an Adjusted EPS of $1.26, which beat the consensus ...